Synopsis
0
EU WC
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Neomycin
2. Neomycin Palmitate
3. Neomycin Sulfate
1. Neomycin Sulfate
2. 1405-10-3
3. Neomycin Trisulfate Hydrate
4. Akos016010116
Molecular Weight | 712.7 g/mol |
---|---|
Molecular Formula | C23H48N6O17S |
Hydrogen Bond Donor Count | 15 |
Hydrogen Bond Acceptor Count | 23 |
Rotatable Bond Count | 9 |
Exact Mass | 712.27966526 g/mol |
Monoisotopic Mass | 712.27966526 g/mol |
Topological Polar Surface Area | 436 Ų |
Heavy Atom Count | 47 |
Formal Charge | 0 |
Complexity | 953 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 18 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Neomycin sulfate |
Drug Label | Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomycesfradiae. Structurally, neomycin sulfate may be represented as follows:Chemically, i... |
Active Ingredient | Neomycin sulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Oman Pharm Products; Teva; X Gen Pharms |
2 of 2 | |
---|---|
Drug Name | Neomycin sulfate |
Drug Label | Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomycesfradiae. Structurally, neomycin sulfate may be represented as follows:Chemically, i... |
Active Ingredient | Neomycin sulfate |
Dosage Form | Tablet |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Oman Pharm Products; Teva; X Gen Pharms |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
Neomycin Sulfate, Micronised And Non-micronised
Certificate Number : R1-CEP 1999-184 - Rev 03
Status : Valid
Issue Date : 2020-04-21
Type : Chemical
Substance Number : 197
Certificate Number : R1-CEP 2017-006 - Rev 00
Status : Valid
Issue Date : 2023-04-13
Type : Chemical and TSE
Substance Number : 197
Certificate Number : R1-CEP 2001-317 - Rev 00
Status : Valid
Issue Date : 2010-09-07
Type : Chemical
Substance Number : 197
Certificate Number : R0-CEP 2022-013 - Rev 01
Status : Valid
Issue Date : 2023-02-15
Type : Chemical and TSE
Substance Number : 197
Certificate Number : R1-CEP 2011-029 - Rev 01
Status : Valid
Issue Date : 2020-02-27
Type : Chemical and TSE
Substance Number : 197
NDC Package Code : 51927-1167
Start Marketing Date : 2002-07-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 0009-5238
Start Marketing Date : 2014-07-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66405-0005
Start Marketing Date : 2017-12-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51671-0010
Start Marketing Date : 2010-12-17
End Marketing Date : 2027-06-08
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49452-4830
Start Marketing Date : 1986-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 55718-163
Start Marketing Date : 1994-07-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 55718-145
Start Marketing Date : 1995-10-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 55718-162
Start Marketing Date : 1996-10-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 65876-0004
Start Marketing Date : 2017-07-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1[BAU]/[BAU])
Marketing Category : BULK INGREDIENT
NDC Package Code : 65876-0002
Start Marketing Date : 2017-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...
About the Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering g...
About the Company : Pharm-Rx has earned an outstanding reputation since its establishment in 1991, serving as a reputable importer and distributor of active ingredients to the pharmaceutical, nutritio...
About the Company : Pfizer CentreOne® is an altogether different global contract development and manufacturing organization (CDMO), and a leading supplier of specialty APIs and intermediates.
...
About the Company : Anhui Sinotech Industrial Co.,Ltd is specially engaged in international marketing of food/feed additive,pesticides and chemicals. We are devoted ourselves to make the life better,a...
About the Company : Arudavis Labs is in the business of manufacturing and trading of Active Pharmaceutical Ingredients and Formulations. We have been serving the Pharmaceutical and Biotechnology Indus...
About the Company : Dorrapharma is engaged in R&D, manufacture and market of intermediate, API (Active Pharmaceutical Ingredients) and formulation. We stick to raise the value both for the company and...
About the Company : QINGDAO QINGMEI BIOTECH(hereinafter referred to as Qingmei) is a specialized pharmaceutical company founded by DAYON INTERNATIONAL HOLDING LIMITED, which is to expand international...
About the Company : Founded in 1968 and based in the historic city of Leshan, Sichuan Long March Pharmaceutical Co., Ltd. is a major antibiotic API manufacturer in Southwest China. It operates under t...
About the Company : Established in 2002, Tecoland represents selected cGMP manufacturers with proven capabilities in organic synthesis, fermentation production as well as process and method developmen...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
69
PharmaCompass offers a list of Neomycin Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Neomycin Sulfate manufacturer or Neomycin Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Neomycin Sulfate manufacturer or Neomycin Sulfate supplier.
PharmaCompass also assists you with knowing the Neomycin Sulfate API Price utilized in the formulation of products. Neomycin Sulfate API Price is not always fixed or binding as the Neomycin Sulfate Price is obtained through a variety of data sources. The Neomycin Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Neomycin Sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Neomycin Sulfate, including repackagers and relabelers. The FDA regulates Neomycin Sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Neomycin Sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Neomycin Sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Neomycin Sulfate supplier is an individual or a company that provides Neomycin Sulfate active pharmaceutical ingredient (API) or Neomycin Sulfate finished formulations upon request. The Neomycin Sulfate suppliers may include Neomycin Sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Neomycin Sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Neomycin Sulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Neomycin Sulfate active pharmaceutical ingredient (API) in detail. Different forms of Neomycin Sulfate DMFs exist exist since differing nations have different regulations, such as Neomycin Sulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Neomycin Sulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Neomycin Sulfate USDMF includes data on Neomycin Sulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Neomycin Sulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Neomycin Sulfate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Neomycin Sulfate Drug Master File in Japan (Neomycin Sulfate JDMF) empowers Neomycin Sulfate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Neomycin Sulfate JDMF during the approval evaluation for pharmaceutical products. At the time of Neomycin Sulfate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Neomycin Sulfate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Neomycin Sulfate Drug Master File in Korea (Neomycin Sulfate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Neomycin Sulfate. The MFDS reviews the Neomycin Sulfate KDMF as part of the drug registration process and uses the information provided in the Neomycin Sulfate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Neomycin Sulfate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Neomycin Sulfate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Neomycin Sulfate suppliers with KDMF on PharmaCompass.
A Neomycin Sulfate CEP of the European Pharmacopoeia monograph is often referred to as a Neomycin Sulfate Certificate of Suitability (COS). The purpose of a Neomycin Sulfate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Neomycin Sulfate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Neomycin Sulfate to their clients by showing that a Neomycin Sulfate CEP has been issued for it. The manufacturer submits a Neomycin Sulfate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Neomycin Sulfate CEP holder for the record. Additionally, the data presented in the Neomycin Sulfate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Neomycin Sulfate DMF.
A Neomycin Sulfate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Neomycin Sulfate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Neomycin Sulfate suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Neomycin Sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Neomycin Sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Neomycin Sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Neomycin Sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Neomycin Sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Neomycin Sulfate suppliers with NDC on PharmaCompass.
Neomycin Sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Neomycin Sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Neomycin Sulfate GMP manufacturer or Neomycin Sulfate GMP API supplier for your needs.
A Neomycin Sulfate CoA (Certificate of Analysis) is a formal document that attests to Neomycin Sulfate's compliance with Neomycin Sulfate specifications and serves as a tool for batch-level quality control.
Neomycin Sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Neomycin Sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Neomycin Sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Neomycin Sulfate EP), Neomycin Sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Neomycin Sulfate USP).